Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Breelyn Ann Wilky

TitleAssociate Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/724-6429

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Subbiah V, Chawla SP, Conley AP, Wilky BA, Tolcher A, Lakhani NJ, Berz D, Andrianov V, Crago W, Holcomb M, Hussain A, Veldstra C, Kalabus J, O'Neill B, Senne L, Rowell E, Heidt AB, Willis KM, Eckelman BP. Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma. Clin Cancer Res. 2023 08 15; 29(16):2988-3003. PMID: 37265425.
      View in: PubMed
    2. Ludwig MP, Galbraith MD, Eduthan NP, Hill AA, Clay MR, Tellez CM, Wilky BA, Elias A, Espinosa JM, Sullivan KD. Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway. Cancer Res. 2023 08 01; 83(15):2543-2556. PMID: 37205634.
      View in: PubMed
    3. Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, Sokol ES, Frampton G, Soares HP, Puri S, Swami U, Wilky B, Hosein P, Trent J, Lopes GL, Park W, Garrido-Laguna I. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. J Immunother Cancer. 2023 08; 11(8). PMID: 37586768.
      View in: PubMed
    4. Maleddu A, Zhu J, Clay MR, Wilky BA. Current therapies and future prospective for locally aggressive mesenchymal tumors. Front Oncol. 2023; 13:1160239. PMID: 37546427.
      View in: PubMed
    5. Randolph ME, Afifi M, Gorthi A, Weil R, Wilky BA, Weinreb J, Ciero P, Ter Hoeve N, van Diest PJ, Raman V, Bishop AJR, Loeb DM. RNA Helicase DDX3 Regulates RAD51 Localization and DNA Damage Repair in Ewing Sarcoma. bioRxiv. 2023 Jun 10. PMID: 37333164.
      View in: PubMed
    6. Wilky BA, Maleddu A. Much Ado about ASPS: The Rapidly Changing Treatment Paradigms of 2022. Clin Cancer Res. 2023 04 03; 29(7):1163-1166. PMID: 36692840.
      View in: PubMed
    7. Gounder M, Ratan R, Alcindor T, Sch?ffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S, Chawla S, D'Amato G, Federman N, Merriam P, Van Tine BA, Vincenzi B, Benson C, Bui NQ, Chugh R, Tinoco G, Charlson J, Dileo P, Hartner L, Lapeire L, Mazzeo F, Palmerini E, Reichardt P, Stacchiotti S, Bailey HH, Burgess MA, Cote GM, Davis LE, Deshpande H, Gelderblom H, Grignani G, Loggers E, Philip T, Pressey JG, Kummar S, Kasper B. Nirogacestat, a ?-Secretase Inhibitor for Desmoid Tumors. N Engl J Med. 2023 Mar 09; 388(10):898-912. PMID: 36884323.
      View in: PubMed
    8. Carter BM, Bronsert MR, Wilky BA, McCarter MD. Mucosal Ulceration in Gastrointestinal Stromal Tumor is an Independent Predictor of Progression-Free Survival. J Surg Res. 2023 04; 284:221-229. PMID: 36587482.
      View in: PubMed
    9. Nathenson MJ, Hu J, Ratan R, Somaiah N, Hsu R, DeMaria PJ, Catoe HW, Pang A, Subhawong TK, Amini B, Sweet K, Feister K, Malik K, Jagannathan J, Braschi-Amirfarzan M, Sheren J, Caldas Y, Moreno Tellez C, Rosenberg AE, Lazar AJ, Maki RG, Benedetto P, Cohen J, Trent JC, Ravi V, Patel S, Wilky BA. Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study. Clin Cancer Res. 2022 09 15; 28(18):4092-4104. PMID: 35180772.
      View in: PubMed
    10. Stacchiotti S, Maria Frezza A, Demetri GD, Blay JY, Bajpai J, Baldi GG, Baldini EH, Benjamin RS, Bonvalot S, Bov?e JVMG, Callegaro D, Casali PG, D'Angelo SP, Davis EJ, Dei Tos AP, Demicco EG, Desai J, Dileo P, Eriksson M, Gelderblom H, George S, Gladdy RA, Gounder MM, Gupta AA, Haas R, Hayes A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Maestro R, Martin Broto J, Maki RG, Miah AB, Palmerini E, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Strauss SJ, Tap WD, Thomas DM, Trama A, Trent JC, van der Graaf WTA, van Houdt WJ, von Mehren M, Wilky BA, Fletcher CDM, Gronchi A, Miceli R, Wagner AJ. Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. Cancer Treat Rev. 2022 Nov; 110:102455. PMID: 36031697.
      View in: PubMed
    11. Moreno Tellez C, Leyfman Y, D'Angelo SP, Wilky BA, Dufresne A. Immunotherapy in Sarcoma: Where Do Things Stand? Surg Oncol Clin N Am. 2022 07; 31(3):381-397. PMID: 35715140.
      View in: PubMed
    12. Kasper B, Wilky BA. Sounding the Alarm on Leiomyosarcoma Recurrence: Role of Circulating Tumor DNA. Clin Cancer Res. 2022 06 13; 28(12):2480-2481. PMID: 35412607.
      View in: PubMed
    13. Florou V, Wilky BA. Emerging mechanisms of immunotherapy resistance in sarcomas. Cancer Drug Resist. 2022; 5(1):199-213. PMID: 35582530.
      View in: PubMed
    14. Smith BD, Kaufman MD, Wise SC, Ahn YM, Caldwell TM, Leary CB, Lu WP, Tan G, Vogeti L, Vogeti S, Wilky BA, Davis LE, Sharma M, Ruiz-Soto R, Flynn DL. Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages. Mol Cancer Ther. 2021 11; 20(11):2098-2109. PMID: 34433663.
      View in: PubMed
    15. Subhawong TK, Feister K, Sweet K, Alperin N, Kwon D, Rosenberg A, Trent J, Wilky BA. MRI Volumetrics and Image Texture Analysis in Assessing Systemic Treatment Response in Extra-Abdominal Desmoid Fibromatosis. Radiol Imaging Cancer. 2021 07; 3(4):e210016. PMID: 34213370.
      View in: PubMed
    16. Florou V, Wilky BA. Current Management of Angiosarcoma: Recent Advances and Lessons From the Past. Curr Treat Options Oncol. 2021 06 07; 22(7):61. PMID: 34097172.
      View in: PubMed
    17. Florou V, Puri S, Garrido-Laguna I, Wilky BA. Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. Ann Transl Med. 2021 Jun; 9(12):1035. PMID: 34277835.
      View in: PubMed
    18. Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bov?e JVMG, Callegaro D, Casali PG, Chiang RC, Demetri GD, Demicco EG, Desai J, Eriksson M, Gelderblom H, George S, Gounder MM, Gronchi A, Gupta A, Haas RL, Hayes-Jardon A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Lim J, Chirlaque L?pez MD, Maestro R, Marcos-Gragera R, Martin Broto J, Matsuda T, Mir O, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Sundby Hall K, Tap WD, Thomas DM, van der Graaf WTA, van Houdt WJ, Visser O, von Mehren M, Wagner AJ, Wilky BA, Won YJ, Fletcher CDM, Dei Tos AP, Trama A. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021 08 15; 127(16):2934-2942. PMID: 33910263.
      View in: PubMed
    19. Chang YC, Stoyanova R, Danilova S, Pretell-Mazzini JA, Kerr DA, Wilky BA, Subhawong T. Radiomics on radiography predicts giant cell tumor histologic response to denosumab. Skeletal Radiol. 2021 Sep; 50(9):1881-1887. PMID: 33733693.
      View in: PubMed
    20. Kasper B, Achee A, Schuster K, Wilson R, van Oortmerssen G, Gladdy RA, Hemming ML, Huang P, Ingham M, Jones RL, Pollack SM, Reinke D, Sanfilippo R, Schuetze SM, Somaiah N, Van Tine BA, Wilky B, Okuno S, Trent J. Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients-A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). Cancers (Basel). 2021 Feb 20; 13(4). PMID: 33672607.
      View in: PubMed
    21. Kerr DA, Brcic I, Diaz-Perez JA, Shih A, Wilky BA, Pretell-Mazzini J, Subhawong TK, Nielsen GP, Rosenberg AE. Immunohistochemical Characterization of Giant Cell Tumor of Bone Treated With Denosumab: Support for Osteoblastic Differentiation. Am J Surg Pathol. 2021 01; 45(1):93-100. PMID: 32773532.
      View in: PubMed
    22. Muir LD, Woelfle JD, Schowinsky J, Wilky BA. High grade sarcoma presenting as multifocal recurrent seromas after inguinal hernia repair: A case report. Rare Tumors. 2020; 12:2036361320975746. PMID: 33489055.
      View in: PubMed
    23. Li L, Hu X, Eid JE, Rosenberg AE, Wilky BA, Ban Y, Sun X, Galoian K, DeSalvo J, Yue J, Chen XS, Blonska M, Trent JC. Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth. Cancers (Basel). 2020 Jan 06; 12(1). PMID: 31935911.
      View in: PubMed
    24. Kerr DA, Pinto A, Subhawong TK, Wilky BA, Schlumbrecht MP, Antonescu CR, Nielsen GP, Rosenberg AE. Pericytoma With t(7;12) and ACTB-GLI1 Fusion: Reevaluation of an Unusual Entity and its Relationship to the Spectrum of GLI1 Fusion-related Neoplasms. Am J Surg Pathol. 2019 12; 43(12):1682-1692. PMID: 31567194.
      View in: PubMed
    25. Florou V, Rosenberg AE, Wieder E, Komanduri KV, Kolonias D, Uduman M, Castle JC, Buell JS, Trent JC, Wilky BA. Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother Cancer. 2019 Nov 06; 7(1):285. PMID: 31694703.
      View in: PubMed
    26. Florou V, Trent JC, Wilky BA. Precision medicine in gastrointestinal stromal tumors. Discov Med. 2019 Nov-Dec; 28(155):267-276. PMID: 32053767.
      View in: PubMed
    27. Ramachandran I, Lowther DE, Dryer-Minnerly R, Wang R, Fayngerts S, Nunez D, Betts G, Bath N, Tipping AJ, Melchiori L, Navenot JM, Glod J, Mackall CL, D'Angelo SP, Araujo DM, Chow WA, Demetri GD, Druta M, Van Tine BA, Grupp SA, Abdul Razak AR, Wilky B, Iyengar M, Trivedi T, Winkle EV, Chagin K, Amado R, Binder GK, Basu S. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J Immunother Cancer. 2019 10 24; 7(1):276. PMID: 31651363.
      View in: PubMed
    28. Disel U, Madison R, Abhishek K, Chung JH, Trabucco SE, Matos AO, Frampton GM, Albacker LA, Reddy V, Karadurmus N, Benson A, Webster J, Paydas S, Cabanillas R, Nangia C, Ozturk MA, Millis SZ, Pal SK, Wilky B, Sokol ES, Gay LM, Soman S, Ganesan S, Janeway K, Stephens PJ, Zhu VW, Ou SI, Lovly CM, Gounder M, Schrock AB, Ross JS, Miller VA, Klempner SJ, Ali SM. The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. Oncologist. 2020 01; 25(1):e39-e47. PMID: 31604903.
      View in: PubMed
    29. Florou V, Rosenberg AE, Wieder E, Komanduri KV, Kolonias D, Uduman M, Castle JC, Buell JS, Trent JC, Wilky BA. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother Cancer. 2019 08 08; 7(1):213. PMID: 31395100.
      View in: PubMed
    30. Wilky BA. Immune checkpoint inhibitors: The linchpins of modern immunotherapy. Immunol Rev. 2019 07; 290(1):6-23. PMID: 31355494.
      View in: PubMed
    31. Hall F, Villalobos V, Wilky B. Future directions in soft tissue sarcoma treatment. Curr Probl Cancer. 2019 08; 43(4):300-307. PMID: 31229264.
      View in: PubMed
    32. Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, Wieder ED, Kolonias D, Rosenberg AE, Kerr DA, Sfakianaki E, Foley M, Merchan JR, Komanduri KV, Trent JC. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol. 2019 06; 20(6):837-848. PMID: 31078463.
      View in: PubMed
    33. Trucco MM, Meyer CF, Thornton KA, Shah P, Chen AR, Wilky BA, Carrera-Haro MA, Boyer LC, Ferreira MF, Shafique U, Powell JD, Loeb DM. A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas. Clin Sarcoma Res. 2018; 8:21. PMID: 30410720.
      View in: PubMed
    34. Wilky BA, Villalobos VM. Emerging Role for Precision Therapy Through Next-Generation Sequencing for Sarcomas. JCO Precis Oncol. 2018 Nov; 2:1-4. PMID: 35135156.
      View in: PubMed
    35. Ramey SJ, Yechieli R, Zhao W, Kodiyan J, Asher D, Chinea FM, Patel V, Reis IM, Wang L, Wilky BA, Subhawong T, Trent JC. Limb-sparing surgery plus radiotherapy results in superior survival: an analysis of patients with high-grade, extremity soft-tissue sarcoma from the NCDB and SEER. Cancer Med. 2018 09; 7(9):4228-4239. PMID: 30030882.
      View in: PubMed
    36. Espejo AP, Ramdial JL, Wilky BA, Kerr DA, Trent JC. A nonrandom association of sarcoidosis in patients with gastrointestinal stromal tumor and other sarcomas. Rare Tumors. 2018; 10:2036361318787626. PMID: 30038741.
      View in: PubMed
    37. Khazeni K, LaBove H, Wilky B, Rosenberg AE, Paulus E, Chim H, Pearson JM, Yakoub D. Myoepithelial carcinoma or epithelioid sarcoma - A rare diagnosis with poor prognosis. A case report and review of literature. Int J Surg Case Rep. 2018; 49:239-243. PMID: 30053614.
      View in: PubMed
    38. Ezuddin NS, Pretell-Mazzini J, Yechieli RL, Kerr DA, Wilky BA, Subhawong TK. Local recurrence of soft-tissue sarcoma: issues in imaging surveillance strategy. Skeletal Radiol. 2018 Dec; 47(12):1595-1606. PMID: 29785452.
      View in: PubMed
    39. Sebio A, Wilky BA, Keedy VL, Jones RL. The current landscape of early drug development for patients with sarcoma in the immunotherapy era. Future Oncol. 2018 May; 14(12):1197-1211. PMID: 29699407.
      View in: PubMed
    40. Florou V, Wilky BA. Current and Future Directions for Angiosarcoma Therapy. Curr Treat Options Oncol. 2018 03 08; 19(3):14. PMID: 29520447.
      View in: PubMed
    41. Upadhyaya SA, McGee RB, Wilky BA, Broniscer A. Malignant progression of a peripheral nerve sheath tumor in the setting of rhabdoid tumor predisposition syndrome. Pediatr Blood Cancer. 2018 07; 65(7):e27030. PMID: 29512865.
      View in: PubMed
    42. Alavi SN, Florou V, Tinoco G, Trent JC, Wilky BA. A precision medicine approach in sarcoma: identification of patients who may benefit from early use of pazopanib. Discov Med. 2018 03; 25(137):131-144. PMID: 29641974.
      View in: PubMed
    43. Florou V, Wilky BA, Trent JC. Latest advances in adult gastrointestinal stromal tumors. Future Oncol. 2017 Oct; 13(24):2183-2193. PMID: 28984483.
      View in: PubMed
    44. Reiss KA, Rangachari D, Cosgrove D, Wilky B, Donehower R. Growing Pains: a Simulation-Based Curriculum for Improving the Transition to Hematology/Oncology Fellowship. J Cancer Educ. 2017 Sep; 32(3):496-502. PMID: 26768145.
      View in: PubMed
    45. Tan Y, Trent JC, Wilky BA, Kerr DA, Rosenberg AE. Current status of immunotherapy for gastrointestinal stromal tumor. Cancer Gene Ther. 2017 Mar; 24(3):130-133. PMID: 28186088.
      View in: PubMed
    46. Wilky BA, Jones RL, Keedy VL. The Current Landscape of Early Drug Development for Patients With Sarcoma. Am Soc Clin Oncol Educ Book. 2017; 37:807-810. PMID: 28561654.
      View in: PubMed
    47. Wilky BA, Goldberg JM. From vision to reality: deploying the immune system for treatment of sarcoma. Discov Med. 2017 01; 23(124):61-74. PMID: 28245428.
      View in: PubMed
    48. Sheth PJ, Del Moral S, Wilky BA, Trent JC, Cohen J, Rosenberg AE, Temple HT, Subhawong TK. Desmoid fibromatosis: MRI features of response to systemic therapy. Skeletal Radiol. 2016 Oct; 45(10):1365-73. PMID: 27502790.
      View in: PubMed
    49. Li L, Paz AC, Wilky BA, Johnson B, Galoian K, Rosenberg A, Hu G, Tinoco G, Bodamer O, Trent JC. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells. PLoS One. 2015; 10(9):e0133813. PMID: 26368816.
      View in: PubMed
    50. Wilky BA, Kim C, McCarty G, Montgomery EA, Kammers K, DeVine LR, Cole RN, Raman V, Loeb DM. RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma. Oncogene. 2016 05 19; 35(20):2574-83. PMID: 26364611.
      View in: PubMed
    51. Subhawong TK, Wilky BA. Value added: functional MR imaging in management of bone and soft tissue sarcomas. Curr Opin Oncol. 2015 Jul; 27(4):323-31. PMID: 26049272.
      View in: PubMed
    52. Tinoco G, Wilky BA, Paz-Mejia A, Rosenberg A, Trent JC. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase. Am Soc Clin Oncol Educ Book. 2015; e648-55. PMID: 25993236.
      View in: PubMed
    53. Wilky BA, Rudek MA, Ahmed S, Laheru DA, Cosgrove D, Donehower RC, Nelkin B, Ball D, Doyle LA, Chen H, Ye X, Bigley G, Womack C, Azad NS. A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours. Br J Cancer. 2015 Jan 06; 112(1):24-31. PMID: 25268371.
      View in: PubMed
    54. Wilky BA, Goldberg JM. Immunotherapy in sarcoma: a new frontier. Discov Med. 2014 Apr; 17(94):201-6. PMID: 24759624.
      View in: PubMed
    55. Kikuchi K, Hettmer S, Aslam MI, Michalek JE, Laub W, Wilky BA, Loeb DM, Rubin BP, Wagers AJ, Keller C. Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma. PLoS Genet. 2014 Jan; 10(1):e1004107. PMID: 24453992.
      View in: PubMed
    56. Trucco MM, Awad O, Wilky BA, Goldstein SD, Huang R, Walker RL, Shah P, Katuri V, Gul N, Zhu YJ, McCarthy EF, Paz-Priel I, Meltzer PS, Austin CP, Xia M, Loeb DM. A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-?B signaling in chordoma biology. PLoS One. 2013; 8(11):e79950. PMID: 24223206.
      View in: PubMed
    57. Wilky BA, Montgomery EA, Guzzetta AA, Ahuja N, Meyer CF. Extrathoracic location and "borderline" histology are associated with recurrence of solitary fibrous tumors after surgical resection. Ann Surg Oncol. 2013 Dec; 20(13):4080-9. PMID: 24046107.
      View in: PubMed
    58. Wilky BA, Meyer CF, Trent JC. Pazopanib in sarcomas: expanding the PALETTE. Curr Opin Oncol. 2013 Jul; 25(4):373-8. PMID: 23666473.
      View in: PubMed
    59. Wilky BA, Loeb DM. Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP. Clin Exp Pharmacol. 2013 Jun; 3(3). PMID: 25664221.
      View in: PubMed
    60. Scannell CA, Pedersen EA, Mosher JT, Krook MA, Nicholls LA, Wilky BA, Loeb DM, Lawlor ER. LGR5 is Expressed by Ewing Sarcoma and Potentiates Wnt/?-Catenin Signaling. Front Oncol. 2013; 3:81. PMID: 23596566.
      View in: PubMed
    61. Thornton KA, Chen AR, Trucco MM, Shah P, Wilky BA, Gul N, Carrera-Haro MA, Ferreira MF, Shafique U, Powell JD, Meyer CF, Loeb DM. A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. Int J Cancer. 2013 Aug 15; 133(4):997-1005. PMID: 23382028.
      View in: PubMed
    Wilky's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (219) concept(s)
    _
    Co-Authors Expand Description
    See all (9) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)